This abstract, presented at the 2021 WMF online conference, reports on a novel dihydroorotate dehydrogenase (DHODH) inhibitor as a potential treatment for COVID-19
WMF 2021 abstract: The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines implicated in COVID-19 disease and is currently being evaluated in the multinational FITE19 Phase 2/3 clinical trial in hospitalized patients
Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
MED-ALL-CORP-2200029 | December 2022
COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.